VestGen Advisors LLC Acquires New Stake in Xencor, Inc. $XNCR

VestGen Advisors LLC bought a new stake in shares of Xencor, Inc. (NASDAQ:XNCR) in the third quarter, Holdings Channel.com reports. The institutional investor bought 102,083 shares of the biopharmaceutical company’s stock, valued at approximately $2,547,000.

Several other institutional investors also recently bought and sold shares of the company. Johnson & Johnson acquired a new position in shares of Xencor during the second quarter worth $12,043,798. Hsbc Holdings PLC boosted its position in shares of Xencor by 114.2% in the 2nd quarter. Hsbc Holdings PLC now owns 125,482 shares of the biopharmaceutical company’s stock worth $2,083,000 after purchasing an additional 66,903 shares in the last quarter. Man Group plc acquired a new stake in shares of Xencor in the 2nd quarter worth $940,000. Primecap Management Co. CA purchased a new position in Xencor during the 2nd quarter worth $163,919,000. Finally, Seven Fleet Capital Management LP purchased a new position in Xencor during the 2nd quarter worth $7,828,524,000.

Xencor Stock Down 2.6%

Shares of XNCR stock opened at $29.21 on Friday. The stock has a market capitalization of $2.17 billion, a PE ratio of -13.46 and a beta of 0.89. Xencor, Inc. has a 52-week low of $10.38 and a 52-week high of $33.60. The stock’s 50-day moving average price is $25.68 and its 200 day moving average price is $16.89.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million during the quarter, compared to analysts’ expectations of $18.89 million. During the same period in the previous year, the company earned ($0.41) EPS. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. Analysts expect that Xencor, Inc. will post -3.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XNCR has been the topic of several recent analyst reports. Royal Bank Of Canada upped their target price on Xencor from $20.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday. Wells Fargo & Company boosted their price target on Xencor from $30.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Barclays set a $45.00 price objective on shares of Xencor and gave the company an “overweight” rating in a research report on Monday. Finally, Bank of America lifted their target price on shares of Xencor from $20.00 to $26.00 and gave the stock a “neutral” rating in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average target price of $39.33.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.